Skinvisible's Invisicare Patent Portfolio Strengthens

Hong Kong Patent Granted for Polymer Technology

LAS VEGAS, Nevada. July 27th, 2010 - Skinvisible, Inc. (SKVI: OTCBB) announced today the Hong Kong Patent Office has issued the Company a patent (No. HK1066971) covering its unique polymer delivery system, Invisicare®. This comprehensive patent is the fourth granted in Asia and the seventh worldwide. The Invisicare patent adds protection in Hong Kong in the areas of "Topical Composition," "Topical Composition Precursor," and "Methods for Manufacturing and Using."

"Patent protection represents a key investment for Skinvisible as it provides our products with long-term market exclusivity," said Mr. Terry Howlett, President and CEO of Skinvisible. "Patents strengthen our ability to license our unique product formulations worldwide, as evidenced by our recent agreements in Europe, China and the United States. We are aggressively pursuing additional licensing opportunities for formulations developed with the Invisicare technology."

The patented Invisicare technology can be applied to a variety of topical products for medical conditions and uses, especially where a controlled release of the active ingredient and substantivity are the desired benefit. Its uniqueness stems from an ability to deliver a wide range of active ingredients, holding them on the skin while providing a controlled release. The cream and gel formulations made with Invisicare have a smooth feel which form an undetectable film that delivers the active ingredient while supporting the skin's natural barrier function. This technology provides life cycle management for topical products that require new patent protection, revitalization and a new story.

Skinvisible holds patent protection for Invisicare in the United States, Australia, India, China, South Korea, Japan and now Hong Kong. The Company has numerous US and international product patents pending covering both the technology and finished product formulations.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com & www.invisicare.com

Corporate Contact:
Doreen McMorran, VP Business Development
Skinvisible Pharmaceuticals, Inc
Phone: 702-433-7154
Email: info@skinvisible.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 31, 2010).